Literature DB >> 20535004

Late onset purple toe syndrome with warfarin successfully treated with fondaparinux.

Joseph P Rindone1, Chadwick K Mellen, James D Eliason.   

Abstract

Purple toe syndrome is a rarely reported adverse effect of warfarin. In all described cases, the syndrome occurred relatively quickly after initiation of warfarin with little recommendation for treatment in patients needing continued anticoagulation. We encountered a patient who developed purple toes after 1 year of warfarin therapy. The warfarin was stopped, and fondaparinux was substituted with prompt resolution of all his symptoms. This is the first case describing late onset purple toe syndrome with warfarin with successful substitution with fondaparinux.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20535004     DOI: 10.1097/MJT.0b013e3181df8e0a

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  2 in total

1.  Warfarin-induced purple toe syndrome successfully treated with apixaban.

Authors:  Holly E Cakebread; Hui Min Knight; Parag R Gajendragadkar; John P Cooper
Journal:  BMJ Case Rep       Date:  2014-06-12

2.  Cholesterol Crystal Embolism Induced by Direct Factor Xa Inhibitor: A First Case Report.

Authors:  Hideaki Oka; Taro Kamimura; Yuki Hiramatsu; Kento Fukumitsu; Rei Iwata; Mika Kondo; Yutaro Hirashima; Seishi Aihara; Atsumi Harada; Kazuhiko Tsuruya
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.